Arcutis Biotherapeutics, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:ARQT
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 373 out of 847
Universe
Global Universe 9789 out of 14951
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Arcutis Biotherapeutics, Inc. |
29.3
Medium
|
373 out of 847 |
Jubilant Pharmova Ltd. |
29.7
Medium
|
390 out of 847 |
Tibet Cheezheng Tibetan Medicine Co., Ltd. |
34.9
High
|
627 out of 847 |
Wave Life Sciences Ltd. |
38.5
High
|
771 out of 847 |
Celltrion Pharm Inc. |
43.1
Severe
|
838 out of 847 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Arcutis Biotherapeutics, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Arcutis Biotherapeutics, Inc.'s Management of ESG Material Risk is Average